Portfolia Named Among Top 10 MedTech VCs of 2024

We are proud to announce that Portfolia has been recognized by MedTech Outlook as one of the Top 10 MedTech VCs of 2024. This prestigious honor highlights our commitment to investing in innovative healthcare solutions that are transforming the lives of millions.

Since launching our first FemTech Fund in 2018, Portfolia has led the way in addressing unmet needs in women's health and active aging through venture capital. With over 45 investments in healthcare companies like Maven Clinic, Everly Health, and Hera Biotech, we are shaping the future of MedTech and advancing solutions for global health challenges.

At Portfolia, we believe that capital has the power to create meaningful change. This recognition underscores the success of our investment strategies, the strength of our portfolio companies, and the dedication of our incredible investors.

About the Award:
The MedTech Outlook Top 10 MedTech VCs award celebrates venture capital firms that demonstrate excellence in driving innovation, advancing MedTech solutions, and creating value for investors and patients alike.

Portfolia launches third Rising America fund for underserved entrepreneurs

By Ryan Hibbison

The debut Rising America fund has generated a TVPI of 3.2x and a gross IRR of 40 percent, lead investor Juliana Garaizar tells Venture Capital Journal.

Portfolia has held a first close on its third Rising America fund, an early-stage vehicle that will invest in companies overlooked by other investors, typically start-ups led by women, people of color and members of the LGBTQ+ community.

Portfolia, which is based in San Mateo, California, has also introduced a separate vehicle specifically for institutional investors. Dubbed the “qualified fund” by the firm, the institutional investor fund is targeting $50 million and will mirror the investments of the accredited fund, which has an undisclosed target.

“For our accredited fund, every day we’re having checks come in and the numbers are higher than they were for Fund II, so we are very confident we’ll get the numbers,” says Rising America fund lead investor Juliana Garaizar, speaking exclusively with Venture Capital Journal .

“Our numbers are so staggering we thought it would be foolish not to take advantage of this and mirror the fund with a qualified one so that family offices and everyone else can take advantage of this.”

Rising America is believed to be the venPture industry’sr first fund series led by five women of color. Its lead investors are Garaizar, Noramay Cadena, Lorine Pendleton and Karen Kerr, while Daphne Dufresne acts as an adviser.

The Rising America team members also work full time on their own projects. Garaizar is founding partner of Energy Tech Nexus, an energy and carbon tech founder community in Houston; Cadena is co-founder and managing partner of 125 Ventures, Kerr is managing director at Exposition Ventures, and Dufresne is managing partner of JBD Holdings.

“Data is the biggest weapon against bias, so the more data we have the easier it is to convince people to invest” - Juliana Garaizar, Portfolia Rising America Fund

Rising America Fund I closed on $5.12 million in October 2020, and Rising America Fund II closed on $6.29 million in December 2022, according to fundraising data from affiliate title Buyouts (registration required). Fund II just recently deployed its last bit of dry powder into Spanish content media provider Canela Media, which is a portfolio company of both Fund I and Fund II, Garaizar says.

Garaizar declined to share the terms of Fund III or name any of its LPs, but says investors that participated in the first close for the accredited fund were return backers of Fund I and II. About half a dozen of them committed more to Fund III than they had to the previous funds, she adds.

The accredited fund is for high-net-worth individuals, which Portfolia has traditionally raised from in the past. The qualified vehicle is the firm’s first fund targeted at institutions, including endowments and family offices.

Institutional LPs that invested in Rising America Fund I and II include financial media company The Motley Fool and impact advisory firm High Impact Ventures.

Up to the Challenge

Raising two funds at the same time may seem like a daunting task given the challenging market for fundraising, but Portfolia is confident that the performance of Rising America Funds I and II will make the process easier. 

Rising America Fund I currently sits at a TVPI of 3.2x and a gross IRR of 40 percent, Garaizar tells VCJ well above both the top-quartile TVPI of 1.27x and IRR of 12.9 percent for vintage-2020 venture funds according to fund performance data from Buyouts. Garaizar adds that fund II is doing “extremely well”, despite closing only recently.

Rising America’s thesis is part of the reason its vehicles have performed so well, Garaizar believes. “Data is the biggest weapon against bias, so the more data we have the easier it is to convince people to invest. These funds are amazing and I think one of the reasons is because these companies are overlooked, their valuations are not that high because of that, which is part of the reason we grow as we have.”

Fund III has not made any investments yet but Garaizar tells VCJ that “it won’t take long” to get started, as the firm “may have some pro rata to deploy” in some of its best-performing companies from Funds I and II.

Fund III plans to invest in 15 companies, and it may have some overlap with its predecessor funds, which have built a portfolio of 27 companies. Both the accredited and qualified funds will make the same investments, though the firm declined to share how the capital allocation will be split between the two vehicles.

Garaizar says Rising America III will specifically target sectors where founders from the hispanic, African American, and LGBTQ+ communities are placing the most emphasis.

“A lot of our previous deals have been in healthtech because these are specific businesses that are more prevalent in these communities,” she tells VCJ. “Fintech because we think a lot about our financial literacy, anything that has to do with food and beverage because we have different tastes, and of course anything that has to do with media because we consume very different kinds, and anything that has to do with fashion.

Some of Portfolia’s previous investments out of the Rising America fund series include the aforementioned Canela Media, which, combined with Portflia’s investment in women- and family-focused digital health platform Maven, drove the performance metrics for Fund I, according to Garaziar. Other representative investments from the funds include personal finance platform MoCaF  (Portfolia participated in its $13 million Series A round in 2021) and family-focused saving and financial literacy application developer Goal Setter (the firm invested in its $3.89 million seed round in 2021).

Garaizar tells VCJ that Portfolia’s model of “learning by doing” and its focus on bringing underrepresented groups into the venture ecosystem has had widespread effects. “We are a fund, but we are also a sort of angel network and educational foundation,” she says.

“What we do is really empower [HNWI] women into feeling like they belong and make sure that these LPs become the leading investors of either Portfolia funds or potentially other [women-led] funds. I think that a lot of other funds out there that are led by women have been built on Portfolia’s track record,of success and all kinds of education.”

Portfolia was founded in 2013 by Trish Costello, who also founded and is CEO emeritus of the Kauffman Fellows Program. Its aim from the start was to invest broadly in underrepresented founders, and companies targeting underrepresented communities. The firm has since amassed an AUM of more than $70 million across 26 funds and special purpose vehicles, and has made moe than 150 investments in companies across sectors, and from pre-seed to pre-IPO.

Portfolia Unveils Rising America III: Driving Unmatched Returns With A New Model for Venture Capital

A Proven Investment Strategy For Institutional Investors, Endowments, and Family Offices With An Estimated 40% IRR Through Diverse-Focused Innovation

SAN MATEO, Calif., Nov. 12, 2024 /PRNewswire/ -- Portfolia, the premiere investing fund designed for the world's most powerful community of women investors, announces the launch of its latest venture capital fund, Rising America III, expanding on its legacy as the highest-performing fund for people of color (POC) in the United States.

Building on the success of Rising America Fund II, which launched last year and had a first close in under24 hours, Rising America III stands out as one of the most active and successful accredited funds dedicated to backing diverse founders who are reshaping industries. Rising America Fund I is a top-performing fund with an estimated 40% IRR. As one of the most active investors in this space, it has backed 27 companies across all sectors and stages, from pre-seed to pre-IPO. It is the only venture capital fund led by five women of color—three African American and two Latina—with an average of 16.4 years of investment experience, including Karen Kerr, Noramay Cadena, Juliana Garaizar, and Lorine Pendleton

Rising America III will also mark as the first qualified fund with Portfolia's unique investment strategy targeting family offices, strategic investors, foundations, and endowments. Its mirrored accredited fund willcontinue to provide individual investors access to invest in traditionally overlooked markets that arebrimming with potential.

"Our third fund represents a crucial opportunity for investors to engage in transformative change at a pivotal moment in our society," says Juliana Garaizar, Fund Partner at Rising America Fund III. "Today's African American, Hispanic, and LGBTQ+ buying power is projected to be $6.6 trillion combined in 2024.This fund embodies our commitment to driving innovation that reflects the rich diversity of our communities, paving the way for a new era where diverse leadership is not just an aspiration, but a realityt hat fuels economic growth and societal progress."

Rising America III represents a breakthrough moment for institutional investors seeking impactful investment opportunities. With over $70 million raised across its previous funds, Portfolia continues to out perform its peers by combining the power of women's networks with a laser focus on underrepresented founders. Key investments have included minority & female-owned Canela, the leading Hispanic media company and home of streaming platform Canela. TV. Mobility Capital Finance ("MoCaFi"), an early-stage fintech company that offers a mobile-first, full-complement banking platform to the 80 million financially underserved in the US; Maven Clinic, the largest women's and family telemedicine network in the US, dramatically improving health outcomes during pregnancy and childbirth and Goal Setter, a family saving, financial literacy and smart spending app that makes it easy for the whole family to go cashless and learn how to be money-smart. Goalsetter is Nickelodeon meets Fintech – it combines the best of Fintech companies like Acorns and CashApp with financial education and gaming that appeals to the whole family.

"The Portfolia model redefines venture investing by filling critical gaps and capturing high-potential opportunities traditionally overlooked by uniform VC firms," says Trish Costello, Founder & CEO of Portfolia. "Through strategic partnerships, Portfolia unites 'dream team' investors with access to high-impact sectors—such as women's health and POC-led companies—where their expertise can drive meaningful change. By handling operational responsibilities, we enable our partners to focus on securing the best deals in these underserved markets. This approach represents innovation in venture capital at the highest performance level a model distinctly effective and not replicable beyond Portfolia." 

About Portfolia

Portfolia is the world's most powerful investing community of women. With over 2,000 members in 18countries and 46 states, Portfolia is directing over $70M AUM across 26 funds/SPVs, which have made over 150 investments in Pre-Seed to Pre-IPO companies. Portfolia venture funds aggregate assets for change, using experience, knowledge, and influence to advance innovations in aging and longevity. To learn more about Portfolia's investment model or our open funds, visit https://www.portfolia.co or follow us on LinkedIn for updates.

'The million-dollar question of this election': Women's health startups are confronting a shifting legal landscape

 
 

By Melia Russell and Rebecca Torrence
Oct 22, 2024, 2:00 AM MST

After a full day of meetings at Julie, a startup that sells a morning-after pill, CEO Amanda E/J Morrison jumped a flight from New York to Boston and headed to a small, private college, where a trivia night awaited her. Dozens of students shuffled into a classroom with plates of chicken tenders, Texas toast, and bright blue boxes of the emergency contraceptive.

Morrison had worked with the Planned Parenthood Generation Action club at Suffolk University to sponsor the event, part of Julie's efforts to win a new generation of consumers. However, she had another, more pressing reason for being there. Julie is doing more campus events to clear up some of the confusion about emergency contraception — namely, that it isn't medication abortion.

Standing at the head of the classroom, Morrison read off a projector screen, "Emergency contraceptives like Julie are legal in how many states? 25, 48, 50, 37." Students tapped their answers into a quiz app. "It's 37," Lily, a spirited sophomore, whispered to her teammates.

In a minute, the correct answer appeared on screen, and the quiet chatter rose to a clamor. Half the teams said 37 states.

"Fifty states, guys. It's everywhere," Morrison said.

When asked why she said 37, Lily said, "Just the way things are going."

In states that outlaw abortion, some patients and politicians worry that contraception could be in legal jeopardy, too. There's no federal law preserving access to birth control, rather, a patchwork of state laws and court decisions holding it in place. Another Trump term could change that.

For Julie, "that's the million dollar question of this election," Morrison said. "We're not worried about some big ban happening in the first hundred days. But how those decisions trickle down — what is presented in Congress as a bill, how the Supreme Court reacts, what trickles down to the states — becomes a real secondary concern," she said.

Founders of women's health startups feel doubly invested in this election, one of the closest presidential races of the century. Half a dozen founders and investors of women's health companies, all women, told Business Insider that if Vice President Kamala Harris wins, it's business as usual. They said another Trump victory creates uncertainty for reproductive health startups, from period trackers to online abortion clinics to embryo banks.

While Harris's presidential campaign has been marked by unrelenting support for reproductive healthcare, including contraception and abortions, Trump's position has been a moving target.

The former president suggested in May that he was "looking at" restrictions on birth control, then walked that position back in a social media post later that day. During the September presidential debate, he called himself a "leader" on IVF, a move that angered parts of his base that have sought to restrict fertility treatments. He said in October that he'd veto a national abortion ban after deflecting the question for months but would support states ordaining their own abortion bans.

Trump's waffling on reproductive rights has put founders of women's health startups on notice. "It is one of the major issues that we're discussing and that our CEOs are focused on — how to continue to provide care to women, especially women of childbearing age," said Trish Costello, founder of Portfolia, an investing platform that pools money from female accredited investors.

The day after the presidential debate, Mika Eddy was vibrating with the weight of the election. The race's outcome could drastically change reproductive rights, foreign policy, gun safety, and climate law — all issues close to Eddy, a 35-year-old Californian and mother of two.

But Eddy also has skin in the game as the chief executive officer of Malama Health, a startup helping women with gestational diabetes access better care. Its doula network assists patients on Medicaid with applying for benefits such as diabetes-friendly meals and medical transport.

Eddy worries that if Trump wins, he would restrict access to the coverage and benefits that her users rely on, weakening one of Malama Health's key services.

"There is this common misperception that, 'we're in California, we're in a liberal state, and so we're safe.' And I don't think that's the case," Eddy said.

For some founders of women's health startups, this election is more than a political contest; it has ramifications for their livelihoods. With so much at stake, they're planning how to handle a scenario where states or courts might impose more limits on reproductive rights.

Hey Jane is a telehealth startup that connects patients to medical providers who offer online appointments and delivers abortion pills to their doorsteps. A year after the Supreme Court overruled Roe v. Wade, ending the constitutional right to abortion, Hey Jane started selling birth control and treatments for urinary tract infections, yeast infections, and herpes, both oral and genital. The new products cushion the business against a "plan E" scenario of a national abortion ban, said Carli Sapir, a Hey Jane investor and founding partner of Amboy Ventures.

"We're thinking about how to make sure those other verticals are in a good place to continue carrying the company forward," said Sapir.

This time last year, one of Hey Jane's rivals, Choix, shut down after three years in service. The company said in a press release that "the stigma and politics surrounding abortion care posed significant fundraising challenges." It raised a $1 million seed round in 2022.

While direct providers of abortion, like Hey Jane, could see major restrictions or shutdowns to their core businesses if Trump returns to the White House, a wider range of companies expect to feel the ripple effects. Startups that seem removed from the front lines, such as those involved with period tracking and fertility treatments, are also preparing for potential challenges.

If a national abortion ban were to occur, apps like Flo Health or Clue might face increased scrutiny, according to Deena Shakir, a general partner at Lux Capital. These apps track when women have their periods and when they miss them. In today's post-Roe America, privacy experts worry that such data could be used to suggest that someone has had or is thinking about having an abortion, potentially putting women at risk of prosecution in certain states.

The stakes could be equally high for companies involved with fertility treatments.

The demand for services like in vitro fertilization, or IVF, and surrogacy has been climbing for years as people have kids later in life and infertility rates increase. That's birthed a global fertility market that includes companies that operate clinics to provide services like egg freezing and IVF, companies that run labs and tests, and firms that help people pay for the procedures.

However, the industry's future is uncertain following attacks on abortion access. The end of Roe v. Wade opened up the legal terrain for states to interfere with access to other reproductive care, said Lauren Berson Sugarman, founder and chief executive officer of Conceive, a startup that offers personalized fertility guidance, including text support from nurses and peer groups.

In Alabama, the state Supreme Court ruled that frozen embryos should be considered children. That put patients and fertility clinics on edge that they could be criminally charged for destroying extra embryos. A handful of Alabama clinics paused IVF treatments while patients throughout the South began moving their embryos to jurisdictions with more stable legal protections.

"We see a lot of patients come to us and say, should I move my embryos out of a red state? Because what happens if they come after IVF?" said Berson Sugarman.

The push for "embryo rights" could have wide-reaching repercussions for startups like Maven Clinic or Carrot Fertility, which offer fertility benefits for employers, and TMRW Life Sciences, a biotech company creating robots for the safe storage of frozen sperm, eggs, and embryos.

Moreover, it could influence the type of research that startups conduct and where. Alice Zheng, a partner at Foreground Capital, explains how the shifting legal landscape might affect companies like Vitra Labs. As a biotech startup working on developing eggs from stem cells for IVF, "they're doing really cutting-edge research for fertility, but they need to think very carefully about where they set up shop," Zheng said. "Some of their research might involve certain types of tissue, which is more closely scrutinized in some areas than others."

Two years ago, in the hours after the Supreme Court ended the constitutional right to an abortion, Morrison's phone started ringing and didn't stop. Investors wanted to know if the ruling would kill Julie's launch in Walmart stores that fall. Job candidates wondered if the company would still exist in six months. Morrison's mom called, concerned for her daughter's future.

"For probably two weeks straight, I was just doing reassurance calls," Morrison said.

While emergency contraception is not the abortion pill and is currently legal in all 50 states, it is continuously confused with the abortion pill, which can have damaging consequences. In June, the medical journal JAMA Network Open published a study that found retail pharmacy fills of Plan B, a leading morning-after pill brand, fell by 65% in states with near-total abortion bans the year after the Dobbs decision, partly due to clinic closures and confusion about its legal status.

That confusion could threaten Julie's sales, and puts the onus of the company to better educate consumers. It sponsors events like trivia nights and sorority house brunches. It has enlisted TikTok influencers to share videos of their drugstore hauls showing how easy it is to buy Julie. In one video, a young woman going back-to-school shopping walks off with a two-count pack of the emergency contraceptive pill. The caption reads, "double majors, not double strollers."

Other startups are urging consumers to fight for reproductive rights at the polls. Eddy's Malama Health has reminders to register to vote in its app and will tell users where their nearest polling station is closer to election day. The company asks for their ZIP codes during onboarding, Eddy explained.

"When you have a baby, you're like, 'I want to vote, but I don't know where to go,'" Eddy said. She hopes the emails will get more pregnant women and new moms to head to the polls. Eddy added that the emails won't support a candidate and are meant as a "nonpartisan resource."

Julie's content isn't political, either. It's not trying to change any minds about abortion rights. The goal is simply to spread awareness among young adults that emergency contraception helps prevent pregnancy, not end it. This way, Morrison said, a woman who is anti-abortion and has unprotected sex can feel confident taking Julie knowing that she isn't compromising her abortion stance.

It was past 9 o'clock on a weekday, and the competition at trivia night was heating up. Students in teams of two or three screamed with delight as they watched their names climb the leaderboard. They competed to win prizes like sex toys and T-shirts with the phrase, "A Better Morning After."

"Morning-after pills end pregnancy. True or false," the club president called out.

Thirty seconds later, the screen showed that every team had answered correctly.

Morrison pumped both fists in the air, beaming her approval.

Melia Russell is a senior correspondent at Insider covering startups and venture capital. She can be reached via the encrypted messaging app Signal at +1 603-913-3085 and email at mrussell@businessinsider.com.

Rebecca Torrence is a correspondent at Business Insider writing about healthcare startups and venture capital. Send her an email at rtorrence@businessinsider.com.

Xandar Kardian's XK300 sensor is one of 5 New Innovations to Help Seniors Live Better

Active Aging & Longevity I and II Company, Xandar Kardian was featured in Fox News Media. Their XK300 sensor can improve the quality of life and independence for older adults by using radar to monitor heart rate, respiratory rate, motion and presence through blankets, clothing, and furniture - without the need for cameras, microphones, wires or wearables

Maven Clinic Members Share Their Story

Nothing fuels us more than seeing our companies succeed. Particularly a company like Maven, who has been growing and disrupting the Women's Health space since 2014.

On their 10-year anniversary, Maven CEO Kate Ryder shares some exciting firsts that happened in the early years and kept the team focused on what matters most: reimagining better care for women and families around the world.